New Data at IASLC 2021 World Conference on Lung Cancer Demonstrates Advantages of Using the Guardant360® Liquid Biopsy Blood Test for Comprehensive Genomic Profiling in Advanced Lung Cancer
September 07, 2021 08:05 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) along with leading academic institutions and pharmaceutical companies will present data demonstrating the...
Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference
September 02, 2021 16:05 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating virtually in the...
Guardant Health to Participate in Morgan Stanley 2020 Healthcare Conference
September 01, 2020 16:03 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the upcoming Morgan Stanley Virtual Healthcare...
Guardant Health Receives FDA Emergency Use Authorization for its Guardant-19 Next Generation Sequencing-Based COVID-19 Test
August 24, 2020 08:05 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) announces that the U.S. Food and Drug Administration (FDA) has granted the Guardant-19 test emergency use...
Guardant Health to Participate in Upcoming August Investor Conferences
August 10, 2020 08:05 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the following investor virtual conferences. UBS...
Guardant Health Guardant360® CDx First FDA-Approved Liquid Biopsy for Comprehensive Tumor Mutation Profiling Across All Solid Cancers
August 07, 2020 14:25 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) announces that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx for tumor mutation...
Guardant Health Reports Second Quarter 2020 Financial Results
August 06, 2020 16:03 ET
|
Guardant Health, Inc.
Q2 2020 Revenue Increase of 23% Over Prior Year Period REDWOOD CITY, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on...
Guardant Health Announces Collaboration with Radius Health to Develop Liquid Biopsy Companion Diagnostic for Elacestrant
July 30, 2020 16:10 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced a strategic collaboration with Radius Health, Inc. (Radius, Nasdaq: RDUS) to pursue...
Guardant Health Announces Webcast of Second Quarter Financial Results on August 6, 2020
July 21, 2020 08:05 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the second quarter 2020 after market close on...
Guardant Health Announces Collaboration with Janssen to Develop Liquid Biopsy Companion Diagnostic
July 08, 2020 08:05 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced a strategic collaboration with Janssen Biotech, Inc. (Janssen) to pursue regulatory...